Clarithromycin/clofazimine/rifabutin

Drug Profile

Clarithromycin/clofazimine/rifabutin

Alternative Names: Clarithromycin/rifabutin/clofazimine; Clofazimine/clarithromycin/rifabutin; Clofazimine/rifabutin/clarithromycin; Myoconda®; RHB-104; Rifabutin/clarithromycin/clofazimine; Rifabutin/clofazimine/clarithromycin

Latest Information Update: 29 Mar 2017

Price : $50

At a glance

  • Originator Centre for Digestive Diseases
  • Developer RedHill Biopharma
  • Class Antibacterials; Macrolides; Phenazines; Rifamycins
  • Mechanism of Action Adenosine triphosphatase inhibitors; P-glycoprotein inhibitors; Phospholipase A2 inhibitors; Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease
  • New Molecular Entity No

Highest Development Phases

  • Phase III Crohn's disease
  • Phase II Multiple sclerosis
  • Preclinical Mycobacterial infections; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus; Type 1 diabetes mellitus

Most Recent Events

  • 21 Mar 2017 RedHill Biopharma announces intention to submit NDA to US FDA for Crohn's disease
  • 21 Mar 2017 RedHill Biopharma plans open-label studies for Crohn's disease
  • 18 Mar 2017 RedHill Biopharma initiates enrolment in the open label extension MAPUS2 trial for Crohn's disease in USA (NCT03009396)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top